AustraliaHealth

Neuren Pharmaceuticals (ASX:NEU) declared a fully franked interim dividend of 15 cents per share for H1 2026.

PolyNovo (ASX:PNV) generated total revenue of $150 million for the year ended June 30, marking a 16.1% increase.

Neuren Pharmaceuticals (ASX:NEU) secured European Commission marketing authorisation for DAYBUE (trofinetide).

Nanosonics (ASX:NAN) increased its annual revenue by 3% to $203.9 million for the financial year ended June 30.

Integral Diagnostics (ASX:IDX) announced its financial results for the year ended June 30, delivering an operating net profit after tax of $47.4 million.

Cyclopharm (ASX:CYC) delivered a record $17.5 million in revenue for the six months ended June 30.

Regis Healthcare (ASX:REG) announced a full-year revenue increase to $1.35 billion alongside an underlying EBITDA of $138 million.

Reece (ASX:REH) increased its FY26 sales revenue by 4.5% to $9.38 billion.

Fisher & Paykel Healthcare (ASX:FPH) increased its 2027 profit guidance to $525–565 million, citing strong hardware demand.

Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$477 million for the first half of 2026.

Sonic Healthcare (ASX:SHL) reported $10.87 billion in annual revenue for FY26, marking a 13% increase.

Alcidion Group (ASX:ALC) reported a 27% increase in FY26 revenue to $51.6 million alongside record profitability metrics.